Hypermarcas (OTCMKTS:HYPMY – Get Free Report) and Traws Pharma (NASDAQ:TRAW – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Insider & Institutional Ownership
8.0% of Traws Pharma shares are held by institutional investors. 8.7% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings for Hypermarcas and Traws Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hypermarcas | 0 | 1 | 0 | 1 | 3.00 |
| Traws Pharma | 1 | 4 | 0 | 0 | 1.80 |
Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 289.11%. Given Traws Pharma’s higher possible upside, analysts clearly believe Traws Pharma is more favorable than Hypermarcas.
Valuation & Earnings
This table compares Hypermarcas and Traws Pharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hypermarcas | $1.38 billion | 1.97 | $213.10 million | $0.52 | 7.43 |
| Traws Pharma | $2.79 million | 1.42 | $9.17 million | ($1.74) | -0.15 |
Hypermarcas has higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than Hypermarcas, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Hypermarcas and Traws Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hypermarcas | 20.07% | 12.58% | 7.00% |
| Traws Pharma | N/A | -23,868.92% | -165.52% |
Risk and Volatility
Hypermarcas has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.
Summary
Hypermarcas beats Traws Pharma on 10 of the 14 factors compared between the two stocks.
About Hypermarcas
Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo QuĂmica and Mantecorp.
About Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
